| Hospital acquired pneumonia
Xacduro vs Zerbaxa
Side-by-side clinical, coverage, and cost comparison for hospital acquired pneumonia.Deep comparison between: Xacduro vs Zerbaxa with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZerbaxa has a higher rate of injection site reactions vs Xacduro based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zerbaxa but not Xacduro, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Xacduro
Zerbaxa
At A Glance
IV infusion
Every 6 hours
Beta-lactam/beta-lactamase inhibitor
IV infusion
Every 8 hours
Cephalosporin/beta-lactamase inhibitor
Indications
- Hospital acquired pneumonia
- Pneumonia, Ventilator-Associated
- Peritonitis
- Urinary tract infection
- Pyelonephritis
- Hospital acquired pneumonia
- VABP
Dosing
Hospital acquired pneumonia, Pneumonia, Ventilator-Associated 1 g sulbactam and 1 g durlobactam every 6 hours by IV infusion over 3 hours in adults with CLcr 45-129 mL/min; adjust dose for other renal function levels; treat for 7 to 14 days.
Peritonitis 1.5 g IV every 8 hours over 1 hour for 4 to 14 days, used in conjunction with metronidazole 500 mg IV every 8 hours; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 5 to 14 days.
Urinary tract infection, Pyelonephritis 1.5 g IV every 8 hours over 1 hour for 7 days; pediatric patients: 30 mg/kg up to 1.5 g every 8 hours for 7 to 14 days.
Hospital acquired pneumonia, VABP 3 g IV every 8 hours over 1 hour for 8 to 14 days in adult patients 18 years and older.
Contraindications
- Known severe hypersensitivity to sulbactam, durlobactam, or other beta-lactam antibacterial drugs
- Known serious hypersensitivity to components of ZERBAXA (ceftolozane and tazobactam), piperacillin/tazobactam, or other members of the beta-lactam class
Adverse Reactions
Most common (>10%) Liver test abnormalities, diarrhea, anemia, hypokalemia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea
Most common (>=5%) Nausea, diarrhea, headache, pyrexia
Serious Hypersensitivity reactions, Clostridioides difficile-associated diarrhea, intracranial hemorrhage, renal impairment/renal failure, hepatic transaminase increased
Pharmacology
Sulbactam is a beta-lactam antibacterial and beta-lactamase inhibitor that exerts bactericidal activity by inhibiting Acinetobacter baumannii-calcoaceticus complex PBP1 and PBP3; durlobactam is a diazabicyclooctane beta-lactamase inhibitor that protects sulbactam from degradation by serine beta-lactamases without intrinsic antibacterial activity against ABC isolates.
Ceftolozane is a cephalosporin antibacterial that inhibits bacterial cell wall biosynthesis by binding to penicillin-binding proteins (PBPs); tazobactam is an irreversible beta-lactamase inhibitor that extends ceftolozane activity against beta-lactamase-producing organisms.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Xacduro
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (0/12) · Qty limit (0/12)
Zerbaxa
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (6/12) · Qty limit (0/12)
UnitedHealthcare
Xacduro
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zerbaxa
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Xacduro
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Zerbaxa
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Xacduro.
No savings programs available for Zerbaxa.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
XacduroView full Xacduro profile
ZerbaxaView full Zerbaxa profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.